RITUXAN HYCELA
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 24 Jan 2024)
What this means for you
Registered since 26 Sept 2017. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §8 & §9 renewal is due by 26 Sept 2027, and its filing window is open now).
Record
- Serial number
- 87264875
- Registration number
- 5298229
- Mark type
- Word mark
- Filed
- 12 Dec 2016
- Published for opposition
- 23 May 2017
- Registered
- 26 Sept 2017
- Next maintenance filing
- §8 & §9 renewal, due by 26 Sept 2027 (grace period to 26 Mar 2028)
- Attorney of record
- Douglas Rettew
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer
Owner
- Biogen MA Inc., Cambridge, MA, US
- Biogen MA Inc., Cambridge, MA, US
- Biogen MA Inc., Cambridge, MA, US
Prior registrations
Prosecution history
- 26 Sept 2026 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 24 Jan 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 24 Jan 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 24 Jan 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 01 Aug 2023 — TEAS SECTION 8 & 15 RECEIVED
- 26 Sept 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 06 Nov 2018 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 26 Sept 2017 — REGISTERED-PRINCIPAL REGISTER
- 22 Aug 2017 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Aug 2017 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 17 Aug 2017 — STATEMENT OF USE PROCESSING COMPLETE
- 24 Jul 2017 — USE AMENDMENT FILED
- 17 Aug 2017 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 24 Jul 2017 — TEAS STATEMENT OF USE RECEIVED
- 18 Jul 2017 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT